Arcutis Starts Phase 1 ARQ-234 Study for Atopic Dermatitis
Arcutis has enrolled the first participant in ARQ-234-131, a Phase 1a/1b, double-blind, randomized, placebo-controlled, first-in-human study of ARQ-234, a...
Jon Napitupulu
Medidata and CRIO Empower Sites, Accelerate Clinical Trials
Near-100% source-to-EDC data accuracy, roughly 90% faster data entry at sites, and adoption across more than 2,500 research sites...
Clearmind Medicine Trial Soars After Safety Board Approval
No serious adverse events were reported and overall tolerability remained favorable in Clearmind Medicine’s second cohort of its Phase...
AIM’s Promising New Ampligen Trial for Pancreatic Cancer
No quantitative efficacy data were disclosed, but AIM ImmunoTech reports positive progression-free survival, overall survival, and safety signals from...
New Osstic™ Bone Filler Enters Clinical Trial for Fractures
No efficacy or safety outcomes have been reported yet. The development moves into humans with MHRA approval for a...
Pacira Reveals Key Real-World Data from IGOR Registry Study
In real-world data from the Innovations in Genicular Outcomes Registry, patients who received liposomal bupivacaine during total knee arthroplasty...
FDA Lifts Clinical Hold on Intellia’s Pivotal ATTR-CM Study
FDA has lifted the clinical hold on Intellia’s Phase 3 MAGNITUDE trial of nexiguran ziclumeran in ATTR-CM after a...
EyePoint Launches Promising Phase 3 DURAVYU™ Trials for DME
EyePoint has begun dosing in two global Phase 3 trials, COMO and CAPRI, evaluating DURAVYU (vorolanib intravitreal insert) in...
Alzheimer’s Study Results Were Foreseeable, Not Astonishing
A 20-year follow-up of the NIH-funded, 2,800-participant ACTIVE study reports that less than 23 hours of speed-of-processing training delivered...
Aprea’s WEE1 Inhibitor Shows Surging, Positive Trial Data
Aprea reported a 50% reduction in target lesions at first assessment and an 87% drop in CA-125 (362 to...